# Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia

> **NCT07327255** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Evergreen Therapeutics, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Pre-eclampsia

## Interventions

- **DRUG:** EG-101

## Key facts

- **NCT ID:** NCT07327255
- **Lead sponsor:** Evergreen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327255, "Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07327255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*